Pelthos Therapeutics (PTHS) Total Non-Current Liabilities (2024 - 2026)
Pelthos Therapeutics (PTHS) posted quarterly Total Non-Current Liabilities of $61.5 million for Q4 2025, up 1405.41% year-over-year from $4.1 million in Q4 2024, and up 46.33% quarter-over-quarter from $42.0 million in Q3 2025.
Pelthos Therapeutics (PTHS) Total Non-Current Liabilities (2024 - 2026) Analysis & Trends
Pelthos Therapeutics' Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $61.5 million for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 1405.41% year-over-year to $61.5 million; the TTM figure through Dec 2025 stood at $61.5 million (up 1405.41% YoY), while the FY2025 annual figure was $61.5 million, up 1405.41% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $61.5 million, up from $42.0 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $61.5 million in Q4 2025, with the low at $4.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Pelthos Therapeutics | 91.09 Mn | 66.53 Mn | 21.23 Mn | 118.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 118.45 Mn |
| Dec 31, 2025 | 61.47 Mn |
| Sep 30, 2025 | 42.01 Mn |
| Dec 31, 2024 | 4.08 Mn |